SCHEMBL3134201

SCHEMBL3134201

F[C@@H]1CNCC[C@@H]1NCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.45
MAOA P21397 2/20 0.45
SSTR4 P31391 2/20 0.43
GRIN2B Q13224 2/20 0.41
GBA1 P04062 1/20 0.41
MAOB P27338 2/20 0.40
SLC6A2 P23975 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40
JAK3 P52333 1/20 0.40
FUCA1 P04066 1/20 0.40
SSTR1 P30872 1/20 0.40
MC4R P32245 1/20 0.40
NAMPT P43490 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39
BACE1 P56817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8651321 1.00 KDM1A (0.45) KDM1AMAOASSTR4GRIN2BGBA1
SCHEMBL21564402 1.00 KDM1A (0.45) KDM1AMAOASSTR4GRIN2BGBA1
SCHEMBL4447151 1.00 KDM1A (0.45) KDM1AMAOASSTR4GRIN2BGBA1
Hydrochloric Acid SCHEMBL518193 0.98 KDM1A (0.44) KDM1AMAOASSTR4GRIN2BGBA1
SCHEMBL20794875 0.86 MEN1 (0.47) KDM1AMAOASSTR4MAOBSLC6A2
SCHEMBL20778668 0.86 MEN1 (0.47) KDM1AMAOASSTR4MAOBSLC6A2
SCHEMBL20795207 0.86 MEN1 (0.47) KDM1AMAOASSTR4MAOBSLC6A2
SCHEMBL20778667 0.86 MEN1 (0.47) KDM1AMAOASSTR4MAOBSLC6A2
SCHEMBL20781110 0.86 MEN1 (0.47) KDM1AMAOASSTR4MAOBSLC6A2
SCHEMBL20778669 0.86 MEN1 (0.47) KDM1AMAOASSTR4MAOBSLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773078-B2 Furin inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-10-03 US disclosed
EP-1853586-B1 ANTIBACTERIAL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2013-07-24 EP disclosed
US-8461170-B2 Chemical compounds ASTRAZENECA AB (SE) 2013-06-11 US disclosed
US-8461170-B2 Chemical compounds ASTRAZENECA AB (SE) 2013-06-11 US disclosed
WO-2012017239-A2 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-09 WO disclosed
US-20120028924-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-02 US disclosed
US-20120028924-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2012-02-02 US disclosed
WO-2010058032-A2 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 WO disclosed
WO-2010058032-A2 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-05-27 WO disclosed
US-5837715-A 3-fluoro-4-aminopiperidine derivatives as 5-HT receptor agonists MERCK SHARP & DOHME LTD. (GB) 1998-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028924-A1 CHEMICAL COMPOUNDS ALK, BRAF, ABL1 KDM1A 485/4885MAOA 1053/4885SSTR4 3094/4885
US-11773078-B2 Furin inhibitors FURIN, TGFB1, PCSK7 KDM1A 3698/4885MAOA 3656/4885SSTR4 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.